Iovance Biotherapeutics, Inc.
825 Industrial Rd
Suite 400
San Carlos
California
94070
United States
Website: http://www.iovance.com/
303 articles about Iovance Biotherapeutics, Inc.
-
Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma
10/5/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma
-
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020
8/7/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) on August 11, 2020 at 2:30pm ET. A live and archived webcast of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com . About Iovance Biotherapeut
-
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdateEnrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer Study
8/6/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported second quarter 2020 financial results and provided a corporate update.
-
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001
8/6/2020
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services t
-
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
7/23/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EDT. To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-24
-
Iovance Biotherapeutics to Present at Upcoming June Conferences
6/8/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following virtual conferences in June
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering
6/4/2020
DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), in a US$603.7 million underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share,
-
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public OfferingOffering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 2.5 Million Shares of Common Stock
6/2/2020
Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the closing of an underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share.
-
Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program
5/29/2020
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up 36.4% Overall Response Rate (ORR) Maintained SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncology’
-
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
5/29/2020
Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the pricing of an underwritten public offering of 16,935,484 shares of its common stock at a public offering price of $31.00 per share
-
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma
5/27/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.
-
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
5/27/2020
Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today announced that it intends to offer and sell $500 million of its common stock, subject to market and other conditions, in an underwritten public offering.
-
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma
5/13/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced new interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.
-
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
5/5/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported first quarter 2020 financial results and provided a corporate update.
-
Iovance Biotherapeutics to Present Updated Data from Clinical Study in Advanced Melanoma at ASCO 2020 Virtual Scientific ProgramOral Presentation of Updated Cohort 2 Data from C-144-01 Clinical Study will be Provided
4/29/2020
Iovance Biotherapeutics, Inc. announced that new interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma will be provided as an oral presentation at the American Society of Clinical Oncology’s upcoming ASCO20 Virtual Scientific Program, to be held May 29-31, 2020.
-
Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
4/27/2020
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2020 financial results on Tuesday, May 5, 2020.
-
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
4/13/2020
Phase 1 Study Combining Tumor Infiltrating Lymphocytes (TIL) and Nivolumab in Non-Small Cell Lung Cancer Funded in Part by Iovance and Stand Up To Cancer
-
Iovance Biotherapeutics to Present at Upcoming Conferences
3/2/2020
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences:
-
Shares of Iovance Biotherapeutics shot up Tuesday on rumors the company could be up for sale.